Allergan (AGN) Offering Possible 22.55% Return Over the Next 24 Calendar Days

Allergan's most recent trend suggests a bearish bias. One trading opportunity on Allergan is a Bear Call Spread using a strike $170.00 short call and a strike $180.00 long call offers a potential 22.55% return on risk over the next 24 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $170.00 by expiration. The full premium credit of $1.84 would be kept by the premium seller. The risk of $8.16 would be incurred if the stock rose above the $180.00 long call strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Allergan is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Allergan is bearish.

The RSI indicator is at 26.67 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Allergan

Jim Cramer: Drug Stocks on the Move
Sat, 17 Feb 2018 00:01:00 +0000
We could be poised for even a further advance PROVIDED that we stay oversold.

Allergan Presents Data at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego
Fri, 16 Feb 2018 23:58:00 +0000
DUBLIN , Feb. 16, 2018 /PRNewswire/ — Allergan plc (NYSE: AGN) today announced that its data will be featured during the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego , February …

Allergan PLC (AGN) Files 10-K for the Fiscal Year Ended on December 31, 2017
Fri, 16 Feb 2018 22:48:05 +0000
Allergan PLC (NYSE:AGN) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.

United Therapeutics reaches patent settlement with Actavis
Fri, 16 Feb 2018 20:31:53 +0000
Silver Spring biotech United Therapeutics Corp.'s share price was largely unchanged Friday after announcing it settled litigation with Actavis Laboratories FL Inc. in a deal that will allow that company to market a generic version of one of United Therapeutics' hypertension drugs. Under the settlement, United Therapeutics (UTHR) grants the Teva Pharmaceutical Industries Ltd. (TEVA) subsidiary a license to manufacture and commercialize a generic version of Orenitram — an extended-release, oral tablet form of treprostinil —beginning June 15, 2027. Actavis had filed a challenge seeking to market the generic Orenitram before United Therapeutics' patents expire between 2024 and 2031.

United Therapeutics settles patent litigation over $157M drug
Fri, 16 Feb 2018 20:16:21 +0000
United Therapeutics has settled patent litigation over a $157 million drug. The company (UTHR) reached an agreement with Actavis Laboratories FL, which is a subsidiary of generic giant Teva Pharmaceuticals, that resolves litigation over certain patents related to one of United Therapeutics' pulmonary arterial hypertension drugs: Orenitram. The settlement agreement allows Actavis to begin manufacturing and commercializing a generic version of the drug in June 2027 or potentially earlier under some circumstances. However, United Therapeutics noted that the agreement doesn't allow Actavis to manufacture generic versions of other products like Tyvaso or Remodulin.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.